Corcept Therapeutics Incorporated
HealthcareNASDAQ:CORT · NASDAQ Capital Market
-$0.34 today
Vol 0.72M · Avg 1.41M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
15.4%
avg 21.1%
ROIC
6.7%
avg 18.1%
ROA
11.9%
avg 19.4%
Analysis
ROE is currently the strongest return metric at 15.4% versus its period average of 21.1%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph K. Belanoff | Co-Founder, President, Chief Executive Officer & Director | $2.40M | — | 69 | $7,035.00 | <0.01% |
William Guyer | Chief Development Officer | $1.16M | — | 58 | $23,985.00 | 0.02% |
Gary Charles Robb | Chief Business Officer & Secretary | $1.09M | — | 63 | $25,681.00 | 0.02% |
Sean Maduck | President of Endocrinology | $933,560.00 | — | 49 | $9,755.00 | <0.01% |
Hazel Hunt | Chief Scientific Officer | $895,156.00 | — | 66 | $140,000.00 | 0.13% |
Atabak Mokari | Chief Financial Officer & Treasurer | $874,847.00 | — | 49 | $16,130.00 | 0.02% |
Amy Flood | Chief Human Resources & Communications Officer | — | — | — | — | — |
Joseph Douglas Lyon | Chief Technology & Accounting Officer | — | — | 48 | $7,035.00 | <0.01% |
Monica Tellado | President of Emerging Markets | — | — | 53 | — | — |
Roberto W. Vieira | President of Oncology | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$3.31M
Sells
43
$40.68M
Net Sentiment
$37.37M
Net selling
Most Active
Guyer William
14 transactions
1–10 of 45
Analysis
Insiders reported 2 buys worth $3.31M and 43 sells worth $40.68M over the last 12 months. That adds up to net selling of $37.37M. Guyer William was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +147.7% | +31.7% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +147.7% over three years. Forward estimates point to Revenue at +31.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.48B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$13.13B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Cytokinetics, Incorporated
NASDAQ:CYTK
$8.73B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Merus N.V.
MRUS
$6.83B
Abivax S.A.
NASDAQ:ABVX
$6.33B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.06B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.08B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages CORT?
Corcept Therapeutics Incorporated (CORT) lists 10 active executives. The top listed executive is Sean Maduck, President of Endocrinology.
Are CORT insiders buying or selling?
Recent insider activity shows net selling of $20.86M.
Explore More
Continue the stock analysis
Jump to another research area for this company.